A249420 Stock Overview
Develops, manufactures, and sells pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A249420 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Ildong Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩11,830.00 |
| 52 Week High | ₩20,500.00 |
| 52 Week Low | ₩10,560.00 |
| Beta | 0.93 |
| 1 Month Change | -1.42% |
| 3 Month Change | -14.77% |
| 1 Year Change | -34.86% |
| 3 Year Change | -64.79% |
| 5 Year Change | -26.28% |
| Change since IPO | -37.87% |
Recent News & Updates
Revenues Not Telling The Story For Ildong Pharmaceutical Co., Ltd. (KRX:249420) After Shares Rise 33%
Aug 20
Is Ildong Pharmaceutical (KRX:249420) A Risky Investment?
Aug 12
Shareholder Returns
| A249420 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 8.0% | 1.8% | -0.04% |
| 1Y | -34.9% | -2.7% | -12.2% |
Return vs Industry: A249420 underperformed the KR Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: A249420 underperformed the KR Market which returned -12.2% over the past year.
Price Volatility
| A249420 volatility | |
|---|---|
| A249420 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A249420 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A249420's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 1,033 | Yun Paul Woongsup | www.ildong.com |
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products.
Ildong Pharmaceutical Co., Ltd. Fundamentals Summary
| A249420 fundamental statistics | |
|---|---|
| Market cap | ₩330.44b |
| Earnings (TTM) | -₩10.65b |
| Revenue (TTM) | ₩610.28b |
0.5x
P/S Ratio-31.0x
P/E RatioIs A249420 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A249420 income statement (TTM) | |
|---|---|
| Revenue | ₩610.28b |
| Cost of Revenue | ₩383.04b |
| Gross Profit | ₩227.24b |
| Other Expenses | ₩237.90b |
| Earnings | -₩10.65b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -381.45 |
| Gross Margin | 37.24% |
| Net Profit Margin | -1.75% |
| Debt/Equity Ratio | 105.9% |
How did A249420 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 06:29 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ildong Pharmaceutical Co., Ltd. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Hyerin Lee | DAOL Investment & Securities Co., Ltd. |
| Jae Hoon Shin | LS Securities Co., Ltd. |